Despite efforts to develop novel treatment strategies, refractory and relapsing sarcoma, and high-risk neuroblastoma continue to have poor prognoses and limited overall survival. Monocyte-derived dendritic cell (DC)-based anti-cancer immunotherapy represents a promising treatment modality in these neoplasias. A DC-based anti-cancer vaccine was evaluated for safety in an academic phase-I/II clinical trial for children, adolescents, and young adults with progressive, recurrent, or primarily metastatic high-risk tumors, mainly sarcomas and neuroblastomas. The DC vaccine was loaded with self-tumor antigens obtained from patient tumor tissue. DC vaccine quality was assessed in terms of DC yield, viability, immunophenotype, production of IL-12 and IL-10, and stimulation of allogenic donor T-cells and autologous T-cells in allo-MLR and auto-MLR, respectively. Here, we show that the outcome of the manufacture of DC-based vaccine is highly variable in terms of both DC yield and DC immunostimulatory properties. In 30% of cases, manufacturing resulted in a product that failed to meet medicinal product specifications and therefore was not released for administration to a patient. Focusing on the isolation of monocytes and the pharmacotherapy preceding monocyte harvest, we show that isolation of monocytes by elutriation is not superior to adherence on plastic in terms of DC yield, viability, or immunostimulatory capacity. Trial patients having undergone monocyte-interfering pharmacotherapy prior to monocyte harvest was associated with an impaired DC-based immunotherapy product outcome. Certain combinations of anti-cancer treatment resulted in a similar pattern of inadequate DC parameters, namely, a combination of temozolomide with irinotecan was associated with DCs showing poor maturation and decreased immunostimulatory features, and a combination of pazopanib, topotecan, and MTD-based cyclophosphamide was associated with poor monocyte differentiation and decreased DC immunostimulatory parameters. Searching for a surrogate marker predicting an adverse outcome of DC manufacture in the peripheral blood complete blood count prior to monocyte harvest, we observed an association between an increased number of immature granulocytes in peripheral blood and decreased potency of the DC-based product as quantified by allo-MLR. We conclude that the DC-manufacturing yield and the immunostimulatory quality of anti-cancer DC-based vaccines generated from the monocytes of patients were not influenced by the monocyte isolation modality but were detrimentally affected by the specific combination of anti-cancer agents used prior to monocyte harvest.

Department of Internal Medicine Hematology and Oncology University Hospital and Medical Faculty Masaryk University Brno Czechia

Department of Pediatric Oncology University Hospital and Faculty of Medicine Masaryk University Brno Czechia

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czechia

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czechia

Transfusion and Tissue Department University Hospital Brno Brno Czechia

Zobrazit více v PubMed

Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al. . Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. (2008) 26:2384–9. 10.1200/JCO.2007.14.7207 PubMed DOI PMC

Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, et al. . Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. (1999) 17:3487–93. 10.1200/JCO.1999.17.11.3487 PubMed DOI

Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. (2016) 36:258–78. 10.1148/rg.2016150099 PubMed DOI

Zapletalova D, Andre N, Deak L, Kyr M, Bajciova V, Mudry P, et al. . Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology. (2012) 82:249–60. 10.1159/000336483 PubMed DOI

Berthold F, Homberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, et al. . Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatr Hematol Oncol. (2017) 34:308–19. 10.1080/08880018.2017.1373314 PubMed DOI

Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, et al. . A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. (2015) 64:1251–60. 10.1007/s00262-015-1731-3 PubMed DOI PMC

Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, et al. . Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. (2016) 22:3182–91. 10.1158/1078-0432.CCR-15-2550 PubMed DOI PMC

Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, et al. . Future paradigms for precision oncology. Oncotarget. (2016) 7:46813–31. 10.18632/oncotarget.9488 PubMed DOI PMC

Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol. (2005) 175:1373–81. 10.4049/jimmunol.175.3.1373 PubMed DOI

Hoffman R, Benz EJ, Jr, Shattil S, Furie B, Cohen H. Hematology: Basic Principles and Practice. Churchill Livingstone; (2005).

Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. (2017) 17:349–62. 10.1038/nri.2017.28 PubMed DOI

Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. . Phenotype, function, and differentiation potential of human monocyte subsets. PLoS ONE. (2017) 12:e0176460. 10.1371/journal.pone.0176460 PubMed DOI PMC

Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. . The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. (2017) 214:1913–23. 10.1084/jem.20170355 PubMed DOI PMC

Sampath P, Moideen K, Ranganathan UD, Bethunaickan R. Monocyte subsets: phenotypes and function in tuberculosis infection. Front Immunol. (2018) 9:1726. 10.3389/fimmu.2018.01726 PubMed DOI PMC

Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. (2017) 11:3009–17. 10.2147/DDDT.S147726 PubMed DOI PMC

Rusten LS, Lyman SD, Veiby OP, Jacobsen SE. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood. (1996) 87:1317–25. PubMed

Kao J, Timmins J, Ozao-Choy J, Packer S. Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. Oncol Lett. (2016) 12:2139–44. 10.3892/ol.2016.4851 PubMed DOI PMC

Briegert M, Kaina B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res. (2007) 67:26–31. 10.1158/0008-5472.CAN-06-3712 PubMed DOI

Bauer M, Goldstein M, Heylmann D, Kaina B. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. PLoS ONE. (2012) 7:e39956. 10.1371/journal.pone.0039956 PubMed DOI PMC

Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, et al. . Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. (2013) 73:2480–92. 10.1158/0008-5472.CAN-12-3542 PubMed DOI

Hu J, Kinn J, Zirakzadeh AA, Sherif A, Norstedt G, Wikstrom AC, et al. . The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. (2013) 172:490–9. 10.1111/cei.12060 PubMed DOI PMC

R Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna: (2019).

Ge C, Li R, Song H, Geng T, Yang J, Tan Q, et al. . Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. BMC Cancer. (2017) 17:884. 10.1186/s12885-017-3859-3 PubMed DOI PMC

Rodriguez J, Castanon E, Perez-Gracia JL, Rodriguez I, Viudez A, Alfaro C, et al. . A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. J Immunother Cancer. (2018) 6:96. 10.1186/s40425-018-0405-z PubMed DOI PMC

Repnik U, Knezevic M, Jeras M. Simple and cost-effective isolation of monocytes from buffy coats. J Immunol Methods. (2003) 278:283–92. 10.1016/S0022-1759(03)00231-X PubMed DOI

Dohnal AM, Graffi S, Witt V, Eichstill C, Wagner D, Ul-Haq S, et al. . Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med. (2009) 13:125–35. 10.1111/j.1582-4934.2008.00304.x PubMed DOI PMC

Zdrazilova Dubska L, Fedorova L, Pilatova K, Mudry P, Hlavackova E, Matoulkova E, et al. TKI pazopanib impaires immunostimulatory properties of monocytes: implication for monocyte-derived DC-based anti-cancer vaccine preparation. Ann Oncol. (2016) 27:18P 10.1093/annonc/mdw525.18 DOI

Trojandt S, Knies D, Pektor S, Ritz S, Mailander V, Grabbe S, et al. . The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunol Immunother. (2013) 62:1315–26. 10.1007/s00262-013-1431-9 PubMed DOI PMC

Cai W, Maldonado NV, Cui W, Harutyunyan N, Ji L, Sposto R, et al. . Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer. (2010) 103:1369–79. 10.1038/sj.bjc.6605927 PubMed DOI PMC

Seitz M, Zwicker M, Loetscher P. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum. (1998) 41:2032–8. 10.1002/1529-0131(199811)41:11<2032::AID-ART19>3.0.CO;2-J PubMed DOI

Cutolo M, Sulli A, Craviotto C, Felli L, Pizzorni C, Seriolo B, et al. . Antiproliferative-antiinflammatory effects of methotrexate and sex hormones on cultured differentiating myeloid monocytic cells (THP-1). Ann N Y Acad Sci. (2002) 966:232–7. 10.1111/j.1749-6632.2002.tb04220.x PubMed DOI

Moller B, Kukoc-Zivojnov N, Okamgba S, Kessler U, Puccetti E, Ottmann OG, et al. . Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors. Rheumatol Int. (2002) 22:60–7. 10.1007/s00296-002-0188-9 PubMed DOI

Perpetuo IP, Caetano-Lopes J, Rodrigues AM, Campanilho-Marques R, Ponte C, Canhao H, et al. . Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-kappabeta expression in monocytes from patients with early rheumatoid arthritis. RMD Open. (2017) 3:e000365. 10.1136/rmdopen-2016-000365 PubMed DOI PMC

Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol. (2014) 14:302–14. 10.1038/nri3660 PubMed DOI

Pilatova K, Bencsikova B, Demlova R, Valik D, Zdrazilova-Dubska L. Myeloid-derived suppressor cells (MDSCs) in patients withsolid tumors: considerations for granulocyte colony-stimulating factor treatment. Cancer Immunol Immunother. (2018) 67:1919–29. 10.1007/s00262-018-2166-4 PubMed DOI PMC

Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, et al. . Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood. (1995) 85:2482–9. PubMed

Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood. (1998) 92:215–22. PubMed

Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T. Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood. (2000) 95:270–6. PubMed

Saito M, Kiyokawa N, Taguchi T, Suzuki K, Sekino T, Mimori K, et al. . Granulocyte colony-stimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol. (2002) 30:1115–23. 10.1016/S0301-472X(02)00889-5 PubMed DOI

Hori S, Heike Y, Takei M, Maruyama M, Inoue Y, Lee JJ, et al. . Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes. J Immunother. (2004) 27:27–35. 10.1097/00002371-200401000-00003 PubMed DOI

Ghanekar SA, Bhatia S, Ruitenberg JJ, Dela Rosa C, Disis ML, Maino VC, et al. . Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. J Immune Based Ther Vaccines. (2007) 5:7. 10.1186/1476-8518-5-7 PubMed DOI PMC

Silveira GF, Wowk PF, Machado AM, Duarte Dos Santos CN, Bordignon J. Immature dendritic cells generated from cryopreserved human monocytes show impaired ability to respond to LPS and to induce allogeneic lymphocyte proliferation. PLoS ONE. (2013) 8:e71291. 10.1371/journal.pone.0071291 PubMed DOI PMC

Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma

Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside